[ Back to EurekAlert! ] Public release date: 14-May-2013
[ | E-mail Share Share ]

Contact: Gina Kirchweger
gxk@stowers.org
816-806-1036
Stowers Institute for Medical Research

Same musicians: Brand new tune

IMAGE: In the absence of Notch2 signaling, newborn mice lack a series of cellular "folds, " that characterize the ciliary body (yellowish-pink cells) as it emerges over the first seven days of...

Click here for more information.

KANSAS CITY, MO—A small ensemble of musicians can produce an infinite number of melodies, harmonies and rhythms. So too, do a handful of workhorse signaling pathways that interact to construct multiple structures that comprise the vertebrate body. In fact, crosstalk between two of those pathways—those governed by proteins known as Notch and BMP (for Bone Morphogenetic Protein) receptors—occurs over and over in processes as diverse as forming a tooth, sculpting a heart valve and building a brain.

A new study by Stowers Institute for Medical Research Investigator Ting Xie, Ph.D., reveals yet another duet played by Notch and BMP signals, this time with Notch calling the tune. That work, published in this week's online issue of PNAS, uses mouse genetics to demonstrate how one Notch family protein, Notch2, shapes an eye structure known as the ciliary body (CB), most likely by ensuring that BMP signals remain loud and clear.

In vertebrates, the CB encircles the lens and performs two tasks essential for normal vision. First, it contains a tiny muscle that reshapes the lens when you change focus, or "accommodate". And it also secretes liquid aqueous humor into the front compartment of the eye where it likely maintains correct eye pressure. Understanding CB construction is critical, as excessive pressure is one risk factor for glaucoma.

Eye development is a relatively new field for Xie, a recognized leader in the study of adult stem cells in the fruit fly: only recently did he branch out into mouse studies. "A few years ago I was asked to participate in a think tank-type meeting to discuss the potential application of cell therapy to treat glaucoma," he says. "I became interested in using retinal progenitor cells to treat diseases like glaucoma or macular degeneration. But I realized that first we needed to understand eye disease at the molecular level." The new study is an important step in that direction.

Previously, investigators knew that once cells that form the CB are established in an embryo, the BMP pathway drives their "morphogenesis", the term used by developmental biologists to describe the process of expanding and then sculpting a committed population of cells into a unique structure. "The Notch2 receptor was previously shown to be expressed in the developing mouse eye," explains Chris Tanzie, M.D., Ph.D., a former graduate student in the Xie lab and the study's co-first author. "But its function was unknown, and no one connected how various signaling pathways direct CB morphogenesis."

To determine what Notch2 was doing in the developing eye, the Stowers team constructed a conditional knockout mouse, meaning that the Notch2 gene is deleted from the genome only in eye cells that give rise to the CB. In normal newborn mice a series of cellular "folds" that characterize the CB emerges over the first 7 days of life. But the mutant knockout mice showed a complete absence of folds, dramatic evidence that Notch2 is required to elaborate a CB.

Furthermore, in normal mice a protein called Jagged-1, which activates Notch2, was expressed in cells adjacent to Notch2-expressing CB cells during the same developmental period. Strikingly, the team's collaborators in Richard Libby's laboratory at the University of Rochester Medical Center, were able to demonstrate that just like the Notch2 mutants, Jagged-1 conditional knockout mice showed almost total loss of CB fold structures, a major hint that Notch2 was switched on by Jagged1 to drive CB formation.

Biochemical and microarray analysis provided further explanation for defects observed after Notch2 loss. Comparison of normal and Notch2-mutant eye cells revealed that not only did cells of mutant mice lose BMP signaling but that expression of two proteins known to interfere with BMP increased in those cells.

"Up-regulation of BMP antagonists following Notch2 loss is an important observation," says Xie. "In other systems people often observe that Notch and BMP cooperatively regulate common targets by transcription factor collaboration at the transcriptional level, but this is a unique mechanism. We find that Notch2 keeps BMP signaling active by inhibiting its inhibitors."

The study's second co-first author is Yi Zhou, a University of Kansas Medical Center graduate student earning his Ph.D. in Xie's lab. "Our work reveals a novel link between Notch and BMP pathways potentially involved in the pathogenesis of glaucoma," says Zhou, noting one more tantalizing implication of the paper. "In addition, mutations in Jagged-1 and Notch2 are thought to underlie the human genetic disease known as Alagille Syndrome. Our work may lead to a better understanding of both."

Alagille Syndrome is an inherited childhood disorder causing defects in organ systems including liver, heart and the skeleton. Xie is equally intrigued by potential connections between his group's observations in the mouse eye and Alagille outcomes in humans. Nonetheless, he remains focused on nailing down how perturbation of the Jagged1-Notch2-BMP axis might cause eye disease.

"We now know how to build better mouse mutants to study CB development. In this work we show that Notch regulates BMP signaling but have not yet determined whether alterations in CB structure actually change interocular pressure," he says. "Answering that question is our future goal."

###

Other members of the Stowers team were Shuyi Chen, Ph.D., Michael Duncan, M.D., Karin Gaudenz, Ph.D., Christopher Seidel, Ph.D., Hua Li, Ph.D., Brandy Lewis, and Andrea Moran. Also contributing were Zhipeng Yan, Ph.D., Richard T. Libby, Ph.D., and Amy E. Kiernan, Ph.D, of the University of Rochester Medical Center.

The study was funded in part by the Stowers Institute for Medical Research, the March of Dimes, and a Research to Prevent Blindness Career Development Award.

About the Stowers Institute for Medical Research

The Stowers Institute for Medical Research is a non-profit, basic biomedical research organization dedicated to improving human health by studying the fundamental processes of life. Jim Stowers, founder of American Century Investments, and his wife, Virginia, opened the Institute in 2000. Since then, the Institute has spent over 900 million dollars in pursuit of its mission.

Currently, the Institute is home to nearly 550 researchers and support personnel; over 20 independent research programs; and more than a dozen technology-development and core facilities.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.